Aims: Lipoprotein lipase (LPL), a pivotal enzyme in lipoprotein metabolism, catalyzes the hydrolysis of triglycerides of very lowdensity lipoproteins and chylomicrons. Assuming that the variants in the promoter of the LPL gene may be associated with changes in lipid metabolism leading to obesity and type 2 diabetes, we examined the role of promoter variants (-T93G and -G53C) in the LPL gene in an urban South Indian population. Methods: The study subjects (619 type 2 diabetic and 731 normal glucose-tolerant (NGT) subjects) were chosen from the Chennai Urban Rural Epidemiology Study, an ongoing population-based study in southern India. The polymorphisms were genotyped using polymerase chain reaction-restriction-fragment length polymorphism (PCR-RFLP). Linkage disequilibrium (LD) was estimated from the estimates of haplotypic frequencies. Results: The two polymorphisms studied were not in LD. The -T93G was not associated with type 2 diabetes but was associated with obesity. 11.5% of the obese subjects (62/541) had the XG(TG þ GG) genotype compared with 6.4% of the nonobese subjects (52/809; P ¼ 0.001). The odds ratio for obesity for the XG genotype was 1.766 (95% CI: 1.19-2.63, P ¼ 0.005). Subjects with XG genotype also had higher body mass index and waist circumference compared with those with TT genotype. With respect to G53C, subjects with the XC(GC þ CC) genotype had 0.527 and 0.531 times lower risk for developing type 2 diabetes and obesity, respectively. Conclusions: Among Asian Indians, the -T93G SNP of the LPL gene is associated with obesity but not type 2 diabetes, whereas the -G53C SNP appears to be protective against both obesity and type 2 diabetes.
Introduction
It is well established that Asian Indians have a greater degree of insulin resistance [1] [2] [3] [4] and increased susceptibility to diabetes 5-8 compared with Europeans. The 'Asian Indian phenotype' refers to the fact that Indians have increased body fat 4, 9, 10 and central body obesity despite low rates of obesity as defined by body mass index (BMI). [7] [8] [9] It is possible that some of the metabolic abnormalities can be explained by genetic factors. In this respect, the lipoprotein lipase (LPL) gene, which has been associated with important metabolic effects in several populations, is of great interest. [11] [12] LPL is an important target gene for the transcriptional factor peroxisome proliferator activated receptor g (PPARg). 13 Transcriptional activation of the LPL gene by fibrates and thiazolidinediones is mediated by PPAR-RXR heterodimers. 14 This activation occurs by the binding of PPARg and the 9-cis retinoic acid receptor (RXR) heterodimers to the PPAR response element (PPRE) sequence (À169 TGCCCTTTCC CCC À157) in the promoter of the LPL gene. 15, 16 Important cis-acting elements in the promoter of LPL gene have been identified that bind DNA-binding proteins and appear to confer basal and/or ligand-mediated LPL gene transcription. 17 DNA variants in the promoter of the LPL gene have been shown to be associated with changes in lipid metabolism leading to type 2 diabetes and its related traits. 12, 18 Hence, this study was performed to evaluate the role of sequence variants in the promoter of LPL gene in relation to diabetes, obesity and related traits.
Patients and methods
This is a case-control study of diabetic and normal glucose tolerant (NGT) subjects selected from the Chennai Urban Rural Epidemiology Study (CURES), an ongoing epidemiology study conducted on a representative population (age X20 years) of Chennai (formerly Madras) in southern India. The methodology of CURES is published elsewhere. 19 Initially, 26 001 individuals were recruited based on a systematic random sampling technique. Self-reported diabetic subjects on drug treatment of diabetes were classified as 'known diabetic subjects'. The known diabetic subjects (n ¼ 1529) were invited to visit the centre for detailed studies.
In addition, every 10th individual of the 26 001 individuals (n ¼ 2600) was invited to undergo oral glucose tolerance tests (OGTT) using 75 g oral glucose load (dissolved in 250 ml of water). Those who were confirmed by OGTT to have 2 h plasma glucose value X11.1 mmol/l (200 mg/dl) based on WHO consulting group criteria were labeled as 'newly detected diabetic subjects' and those with 2 h plasma glucose value o7.8 mmol/l (140 mg/dl) as having normal glucose tolerance (NGT).
As a pilot study, we screened 150 type 2 diabetic and 150 age-and sex-matched NGT subjects for mutations in the region comprising the PPRE sequence of the LPL gene by direct sequencing. The identified variants were studied further in a large number of study subjects (619 type 2 diabetic and 731 NGT subjects) chosen randomly from CURES. All study subjects were genotyped for the presence of the identified variants and these were correlated with clinical and metabolic parameters. Informed consent was obtained from all study participants, and the study was approved by the Institutional Ethics Committee.
The BMI was calculated using the formula, weight (kg)/ height (m . 20 Biochemical analyses were done on Hitachi-912 Autoanalyser (Hitachi, Germany) using kits supplied by Roche Diagnostics (Mannheim, Germany). Fasting plasma glucose (GOD-POD method), serum cholesterol (CHOD-PAP method), serum triglycerides (GPO-PAP method) and high-density lipoprotein (HDL) cholesterol (Direct method-polyethylene glycol-pretreated enzymes) were measured by enzymatic methods. Low-density lipoprotein (LDL) cholesterol was calculated using the Friedewald's formula. Glycated hemoglobin (HbA1C) was estimated by high-performance liquid chromatography using the Variant machine (Bio-Rad, Hercules, CA, USA). Serum insulin concentration was estimated using enzyme-linked immunosorbent assay (Dako, Glostrup, Denmark). Insulin resistance was calculated using the homeostasis assessment (HOMA-IR) model using the following formula:
fasting insulin ðmIU=mlÞÂfasting glucose ðmmol=l=22:5Þ
Genomic DNA was isolated from the whole blood by the phenol-chloroform method of DNA extraction. 21 The polymerase chain reaction (PCR) fragment comprising the SNPs -T93G and -G53C were amplified using the following primers: forward, 5 0 -GCTGATCCATCTTGCCAATGTTA-3 0 ; and reverse, 5
0 -CCGCGGTTTGGCGC TGAGCAAGT-3 0 . SNP -T93G was detected using the enzyme HaeIII and -G53C was detected using BclI. The RFLP products were resolved by 3% agarose gel electrophoresis.
Statistical Package for Social Sciences (SPSS, Windows, version 10.0) was used for statistical analysis. The effects of the two polymorphisms on quantitative and categorical variables were analyzed. Allele frequencies were estimated by gene counting. Agreement with Hardy-Weinberg expectations was tested using a w 2 goodness-of-fit test. One-way ANOVA or Student's t-test as appropriate was used to compare groups for continuous variables. w 2 test was used to compare the proportions of genotypes or alleles. Risk variables were adjusted for age for comparison between different genotypes. Regression analysis was carried out using diabetes as dependent variable and the genotypes as independent variables. Haplotype frequencies were estimated using an Expectation-Maximization (EM) algorithm, which equates each genotypic frequency to the sum of the probabilities of all possible haplotypic configurations resulting in that genotype. Linkage disequilibrium (LD) was estimated from the estimates of haplotypic frequencies.
Results
Compared to NGT subjects, the diabetic subjects had significantly higher BMI (diabetes: 26.174.2 vs NGT: 24.074.7 kg/m 2 , P ¼ 0.003) and waist circumference (diabetes: 92.379.4 vs NGT: 87.2711.4 cm, P ¼ o0.0001). Systolic and diastolic blood pressure (Po0.0001), serum cholesterol (Po0.0001) and triglycerides (Po0.0001) were also significantly higher among subjects with type 2 diabetes compared with NGT subjects (Table 1) .
Direct sequencing of the promoter region comprising the PPRE element of LPL gene revealed two variants, namely, a T-G substitution at the nucleotide position À93 and a G-C substitution at the nucleotide position À53. The frequencies of the -93G and À53C variant alleles were 4.3 and 4.2%, respectively, in the pilot study. The genotype-phenotype analysis in this pilot screening revealed that ÀT93G was associated with the various measures of obesity and ÀG53C was associated with type 2 diabetes and obesity.
The two identified promoter variants, ÀT93G and ÀG53C, were studied further in a large number of study subjects (n ¼ 1350) to examine the role of these variants in relation LPL gene variants, obesity and type 2 diabetes in Asian Indians V Radha et al to type 2 diabetes, obesity and its related traits. The two polymorphisms were not in linkage disequilibrium. The pairwise LD between the two loci (À93T/G and À53G/C) in the LPL gene was not significant at level 0.05, indicating that the loci are unlikely to be in LD. The pairwise LD values (D 0 ) between À93 and À53 loci were 0.0159 (P ¼ 0.7894) in type 2 diabetic subjects and 0.1024 (P ¼ 0.1282) in NGT subjects. Nevertheless, two-sample t-tests were performed to evaluate the differences in haplotypic frequencies between type 2 diabetic and NGT subjects but no significant differences were found.
The genotype and allele frequencies of the sequence substitution in the promoter region at À93 bp were not statistically significant between the NGT and type 2 diabetic subjects ( Table 2 ). Stratification of the study subjects based on obesity according to the Asia Pacific guidelines revealed that the frequency of the pooled genotype class TG and GG (hereafter denoted as 'XG') genotype of À93 T-G SNP was significantly higher among obese subjects (62/541, 11.5%) compared with nonobese subjects (52/809, 6.4%, P ¼ 0.001). Statistically significant differences were observed in the distribution of genotypes (P ¼ 0.001) and alleles (P ¼ 0.002) between obese and nonobese subjects. Regression analysis revealed the odds ratio for obesity for the individuals carrying the XG genotype to be 1 Similarly, type 2 diabetic genotypes of À93 T-G SNP in NGT and type 2 diabetic subjects (data not shown).
The genotype (P ¼ 0.008) and allele (P ¼ 0.044) frequencies of À53 G-C promoter polymorphism of the LPL gene were statistically significant between NGT and type 2 diabetic subjects and the XC appeared to be protective against both obesity and diabetes (Table 3) . Regression analysis revealed the odds ratio (adjusted for age, sex and BMI) for diabetes for XC (GC þ CC) genotype to be 0.527 (95% CI: 0.29-0.96, P ¼ 0.036). To study the role of this variant in obesity-related traits, the study subjects were stratified based on BMI. The genotype and allele frequencies of À53 G-C variant were statistically significant between the obese and nonobese subjects ( Table 3 ). The odds ratio for obesity for the XC genotype was 0.531 (95% CI: 0.30-0.94, P ¼ 0.031) and this remained significant even after adjustment for age, sex and diabetes (OR: 0.561 (95% CI: 0.03-0.99, P ¼ 0.05)). None of 
Discussion
The important finding of this study is that the À93 T-G SNP of the LPL gene is associated with the increased risk of developing obesity, whereas the À53 G-C SNP is associated with the reduced risk of developing obesity and type 2 diabetes in this South Indian population (Figure 1 ). This is one of the first reports investigating the association of these polymorphisms with type 2 diabetes and obesity in Asian Indians. Subjects with the XG genotype of À93 T-G SNP were at 1.766 times higher risk of developing obesity compared with those with TT genotype. Furthermore, subjects with XG genotype had significantly higher BMI and waist circumference values compared with those with TT genotype. The T-G substitution at nucleotide À93 lies 2 bases 5 0 to a totally conserved inverted GA box (5 0 -CCTCCCCCC-3 0 , nt À91 to À83) in the LPL promoter. 22 This motif binds the transcription factors Sp1 and Sp3 and is essential for LPL promoter activity. The basic recognition unit of the Sp family transcription factors is a motif with a consensus sequence 5 0 -(G/T)GGGCGGPu-Pu-Py-3 0 , known as a GC box. Furthermore, GA and GT boxes (or their inverted forms, CT and CA elements) can also bind Sp proteins with similar specificity in the promoters of LPL gene. It is known that the nucleotides flanking this conserved element may influence binding affinity of Sp1 and Sp3. 22 Furthermore, this variant lies within the region of LSE-2, identified by Tanuma et al. 23 as a potential LSE-2, and hence it is possible that this T-to-G change at À93 results specifically in the disruption of LSE-2, leading to increased expression of LPL. Functional studies using luciferase gene as a reporter have shown that the À93G promoter had 24% higher activity than the À93T in a rat smooth muscle cell line. 24 Using a human adrenal cell line, NCIH295, which has been shown to secrete LPL, 25 a similar (18%) increase in luciferase activity was seen with the G allele. 24 Although this variant was not associated with altered lipid profile in this study population, the association of this promoter variant with different measures LPL gene variants, obesity and type 2 diabetes in Asian Indians V Radha et al of obesity suggests it could be an important contributor to obesity and type 2 diabetes in this ethnic group. The À53 G-C promoter polymorphism of the LPL gene was found to be a rare variant in Dutch, Black and Chinese populations. 12 However, in this study population, this variant was significantly associated with the reduced risk of developing obesity and type 2 diabetes. Subjects with the XC genotype had 0.527 times and 0.531 times lower risk for developing type 2 diabetes and obesity. None of the clinical and biochemical parameters were statistically significant between the genotypes of this promoter SNP in NGT and type 2 diabetic subjects. This may be because of the lower frequency of the heterozygous variants in this study. The ÀG53C substitution is located between the CCAAT (nt À65 to À61) and Oct-1 (nt À46 to À39) motifs and within a putative Ca 2 þ -responsive element, 5 0 -TGAGGTTT-3 0 (nt. À54 to À47), similar to the (TGACGTTT) of the c-fos gene promoter. 26 DNase I protection assays have revealed a footprint in the region extending approximately from nt À52 to À35. 27 The À53 substitution may affect the binding of Oct-1 to the octamer site or some of other transcription factors to the putative Ca 2 þ -responsive element. Hence, the location of this variant and its association with type 2 diabetes and obesity seems to reveal that this SNP could have some functional role in this study population. It has been shown that there is significant diversity in allele frequencies at many autosomal loci within different castes in South India. 28 To address the issue of population stratification, a cross-validation using genomic controls was done. 29 A case-control study at six unlinked marker loci believed to be unrelated to the disease under study but known to have allelic diversity among different populations was carried out. The allele frequency difference between cases and controls was not statistically significant at any of the six loci studied. This indicates that the findings in this study are not likely to be an artifact of population sub structuring. In a recent study by Radha et al., 30 the HindIII and Ser447
Ter polymorphisms of the LPL gene were shown to be associated with low HDL cholesterol and hypertriglyceridemia in Asian Indians. This study shows further evidence of the importance of the LPL gene in relation to type 2 diabetes and obesity in this ethnic group. Taken together, the findings in the present study and our earlier study 30 thus confirm that the LPL gene polymorphism is associated with several components of the metabolic syndrome in Asian Indians. However, the findings will need to be confirmed in replication studies and, most importantly, will need to be supported by mechanistic studies.
